Literature DB >> 28475179

mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism.

Aikaterini Lampada1,2, James O'Prey3, Gyorgy Szabadkai4, Kevin M Ryan3, Daniel Hochhauser2, Paolo Salomoni1.   

Abstract

The intracellular autophagic degradative pathway can have a tumour suppressive or tumour-promoting role depending on the stage of tumour development. Upon starvation or targeting of oncogenic receptor tyrosine kinases (RTKs), autophagy is activated owing to the inhibition of PI3K/AKT/mTORC1 signalling pathway and promotes survival, suggesting that autophagy is a relevant therapeutic target in these settings. However, the role of autophagy in cancer cells where the PI3K/AKT/mTORC1 pathway is constitutively active remains partially understood. Here we report a role for mTORC1-independent basal autophagy in regulation of RTK activation and cell migration in colorectal cancer (CRC) cells. PI3K and RAS-mutant CRC cells display basal autophagy levels despite constitutive mTORC1 signalling, but fail to increase autophagic flux upon RTK inhibition. Inhibition of basal autophagy via knockdown of ATG7 or ATG5 leads to decreased phosphorylation of several RTKs, in particular c-MET. Internalised c-MET colocalised with LAMP1-negative, LC3-positive vesicles. Finally, autophagy regulates c-MET phosphorylation via an mTORC2-dependent mechanism. Overall, our findings reveal a previously unappreciated role of autophagy and mTORC2 in regulation of oncogenic RTK activation, with implications for understanding of cancer cell signalling.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28475179      PMCID: PMC5442471          DOI: 10.1038/cdd.2017.41

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  61 in total

1.  A kinase-independent role for EGF receptor in autophagy initiation.

Authors:  Xiaojun Tan; Narendra Thapa; Yue Sun; Richard A Anderson
Journal:  Cell       Date:  2015-01-15       Impact factor: 41.582

2.  Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death.

Authors:  Sandrine Eimer; Marc-Antoine Belaud-Rotureau; Kelly Airiau; Marie Jeanneteau; Elodie Laharanne; Nadège Véron; Anne Vital; Hugues Loiseau; Jean-Philippe Merlio; Francis Belloc
Journal:  Cancer Biol Ther       Date:  2011-06-15       Impact factor: 4.742

Review 3.  p62/SQSTM1/A170: physiology and pathology.

Authors:  Masaaki Komatsu; Shun Kageyama; Yoshinobu Ichimura
Journal:  Pharmacol Res       Date:  2012-07-25       Impact factor: 7.658

4.  Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism.

Authors:  Anne M Strohecker; Eileen White
Journal:  Autophagy       Date:  2013-12-17       Impact factor: 16.016

5.  Intestinal inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune response and suppresses tumour growth.

Authors:  Jonathan Lévy; Wulfran Cacheux; Medhi Ait Bara; Antoine L'Hermitte; Patricia Lepage; Marie Fraudeau; Coralie Trentesaux; Julie Lemarchand; Aurélie Durand; Anne-Marie Crain; Carmen Marchiol; Gilles Renault; Florent Dumont; Franck Letourneur; Myriam Delacre; Alain Schmitt; Benoit Terris; Christine Perret; Mathias Chamaillard; Jean-Pierre Couty; Béatrice Romagnolo
Journal:  Nat Cell Biol       Date:  2015-07-27       Impact factor: 28.824

6.  Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis.

Authors:  Vassiliki Karantza-Wadsworth; Shyam Patel; Olga Kravchuk; Guanghua Chen; Robin Mathew; Shengkan Jin; Eileen White
Journal:  Genes Dev       Date:  2007-07-01       Impact factor: 11.361

7.  Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.

Authors:  Mei-Chuan Tang; Mei-Yi Wu; Ming-Hung Hwang; Ya-Ting Chang; Hui-Ju Huang; Anya Maan-Yuh Lin; James Chih-Hsin Yang
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

Review 8.  Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence.

Authors:  Teresa Troiani; Stefania Napolitano; Carminia Maria Della Corte; Giulia Martini; Erika Martinelli; Floriana Morgillo; Fortunato Ciardiello
Journal:  ESMO Open       Date:  2016-09-16

9.  Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.

Authors:  Harpreet Wasan; Angela M Meade; Richard Adams; Richard Wilson; Cheryl Pugh; David Fisher; Benjamin Sydes; Ayman Madi; Bruce Sizer; Charles Lowdell; Gary Middleton; Rachel Butler; Richard Kaplan; Tim Maughan
Journal:  Lancet Oncol       Date:  2014-04-03       Impact factor: 41.316

10.  Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis.

Authors:  Pengda Liu; Wenjian Gan; Hiroyuki Inuzuka; Adam S Lazorchak; Daming Gao; Omotooke Arojo; Dou Liu; Lixin Wan; Bo Zhai; Yonghao Yu; Min Yuan; Byeong Mo Kim; Shavali Shaik; Suchithra Menon; Steven P Gygi; Tae Ho Lee; John M Asara; Brendan D Manning; John Blenis; Bing Su; Wenyi Wei
Journal:  Nat Cell Biol       Date:  2013-10-27       Impact factor: 28.824

View more
  25 in total

1.  Autophagy and receptor tyrosine kinase signalling: A mTORC2 matter.

Authors:  Aikaterini Lampada; Daniel Hochhauser; Paolo Salomoni
Journal:  Cell Cycle       Date:  2017-09-21       Impact factor: 4.534

Review 2.  The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues.

Authors:  Anna Sebestyén; Titanilla Dankó; Dániel Sztankovics; Dorottya Moldvai; Regina Raffay; Catherine Cervi; Ildikó Krencz; Viktória Zsiros; András Jeney; Gábor Petővári
Journal:  Cancer Metastasis Rev       Date:  2022-01-14       Impact factor: 9.264

3.  Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.

Authors:  Lorena Ligammari; Hang-Mao Lee; Helen J Knowles; Lucia Cottone; Stephen Henderson; Sara Bianco; Christopher Davies; Sandra Strauss; Fernanda Amary; Ana Paula Leite; Roberto Tirabosco; Kristian Haendler; Joachim L Schultze; Javier Herrero; Paul O'Donnell; Agamemnon E Grigoriadis; Paolo Salomoni; Adrienne M Flanagan
Journal:  Cell Death Differ       Date:  2022-08-03       Impact factor: 12.067

Review 4.  Interplay of autophagy, receptor tyrosine kinase signalling and endocytic trafficking.

Authors:  Jane Fraser; Ainara G Cabodevilla; Joanne Simpson; Noor Gammoh
Journal:  Essays Biochem       Date:  2017-12-12       Impact factor: 8.000

5.  CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.

Authors:  Shuai Lu; Yao Yao; Guolong Xu; Chao Zhou; Yuan Zhang; Jie Sun; Runqiu Jiang; Qing Shao; Yun Chen
Journal:  Cell Death Dis       Date:  2018-05-29       Impact factor: 8.469

6.  Activation of the SphK1/ERK/p-ERK pathway promotes autophagy in colon cancer cells.

Authors:  Chunyan Xu; Wenlu Zhang; Shiquan Liu; Wenhong Wu; Mengbin Qin; Jiean Huang
Journal:  Oncol Lett       Date:  2018-04-26       Impact factor: 2.967

Review 7.  The Role of PI3K in Met Driven Cancer: A Recap.

Authors:  Alexia Hervieu; Stéphanie Kermorgant
Journal:  Front Mol Biosci       Date:  2018-10-24

Review 8.  The role of RICTOR downstream of receptor tyrosine kinase in cancers.

Authors:  Ahlem Jebali; Nicolas Dumaz
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

9.  The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer.

Authors:  Dongfang Tang; Dandan Zhao; Yun Wu; Ruyong Yao; Lin Zhou; Liming Lu; Wen Gao; Yifeng Sun
Journal:  J Cell Mol Med       Date:  2018-05-04       Impact factor: 5.295

Review 10.  mTORC2: The other mTOR in autophagy regulation.

Authors:  Josué Ballesteros-Álvarez; Julie K Andersen
Journal:  Aging Cell       Date:  2021-07-12       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.